References

nnp

Neurology, Neuropsychiatry, Psychosomatics

Неврология, нейропсихиатрия, психосоматика

2074-27112310-1342

"IMA-Press", LLC

10.14412/2074-2711-2023-5-79-86

nnp-2108

Research Article

REVIEWS

ОБЗОРЫ

Diagnosis and treatment of depression according to the functional recovery paradigm

Диагностика и терапия депрессий в парадигме восстановления социального функционирования

https://orcid.org/0000-0002-7619-1179

Усов

Г. М.

Usov

G. M.

Григорий Михайлович Усов

644099, Омск, ул. Ленина, 12

Grigory Mikhailovich Usov

Omsk 12, Lenina St., Omsk 644099

usovgm@list.ru

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical University, Ministry of Health of the RussiaRussian Federation

2023

23102023

1557986

2023

Усов Г.М.

Usov G.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://nnp.ima-press.net/nnp/article/view/2108

Since the appearance of the first antidepressants, ideas about the goals of long-term treatment of depression have changed considerably. The prevailing priority in the 1960s to 1980s of relieving current depressive symptoms and ending the current episode – shifted to achieving remission in the early 1990s and functional recovery in the mid-2010s. The general recognition of a new approach to the treatment of depression is reflected in the inclusion of functional disorder in the ICD-11 diagnostic criteria for a depressive episode. The paradigm shift in therapy has been driven by advances in the field of psychopharmacology that have led to the development of antidepressants with a fundamentally new mechanism of action that provides a broader therapeutic effect combined with a more favorable tolerability profile. Agomelatine provides a harmonious and complete reduction of depression symptoms, including those resistant to other antidepressants, and a stable clinical and functional remission of high quality, i.e., it allows the achievement of all three therapeutic goals.

С момента появления первых антидепрессантов представления о целях долгосрочной терапии депрессий претерпели существенные изменения. Приоритет купирования актуальной депрессивной симптоматики с обрывом текущего эпизода, доминировавший в 1960–1980-е годы, был перенесен на достижение ремиссии в начале 1990-х, а затем на достижение функционального выздоровления в середине 2010-х. Проявлением всеобщего признания нового подхода к терапии депрессий стало включение нарушений функционирования в диагностические критерии депрессивного эпизода в Международной классификации болезней 11-го пересмотра. В основе смены терапевтических парадигм лежали достижения в области психофармакологии, благодаря которым появились антидепрессанты спринципиально новым механизмом действия, обеспечивающим большую широту терапевтического эффекта всочетании с более благоприятным профилем переносимости. Агомелатин обеспечивает гармоничную и полную редукцию симптомов депрессии, в том числе резистентных к действию других антидепрессантов, а также достижение стойкой клинической и функциональной ремиссии высокого качества, т. е. делает возможным достижение всех трех целей терапии.

депрессияфункциональное выздоровлениеантидепрессантыагомелатин

depressionfunctional recoveryantidepressantsagomelatine

Статья спонсируется компанией «Сервье»

This article has been supported by Servier

References1

Гаррабе Ж. История шизофрении. Редакторы издания на русском языке М.М. Кабанов, Ю.В. Вид. Москва – Санкт-Петербург; 2000. С. 43.

Garrabe J. History of schizophrenia. Editors of the publication in Russian M.M. Kabanov, Yu.V. Vid. Moscow – St. Petersburg; 2000. P. 43 (In Russ.).

Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 6 Auflage. Leipzig: Barth; 1899.

Рыбаковский Я. Лики маниакально-депрессивного расстройства. Москва: ИД «Городец»; 2019. С. 33.

Rybakovsky Ya. Liki maniakal'no-depressivnogo rasstroystva [Faces of manic-depressive disorder]. Moscow: Gorodets Publishing House; 2019. P. 33 (In Russ.).

Kraepelin E, Barclay RM. Manic-depressive insanity and paranoia. Edinburgh: E. & S. Livingstone; 1921.

Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford; 1979.

Klerman GL, Weisman MW, Rounsaville BJ, Chevron ES. Interpersonal psychotherapy of depression. New York: Basic books; 1984.

Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992 Oct;49(10):809-16. doi: 10.1001/archpsyc.1992.01820100053010

Mueller TI, Keller MB, Leon AC, et al. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry. 1996 Sep;53(9):794-9. doi: 10.1001/archpsyc.1996.01830090040006

Каспер С. Обоснование длительной терапии антидепрессантами. Социальная и клиническая психиатрия. 1995;(1):80-92.

Kasper S. Justification of long-term therapy with antidepressants. Sotsial'naya i klinicheskaya psikhiatriya = Social and Clinical Psychiatry. 1995;(1):80-92 (In Russ.).

Корнетов НА. Депрессивные расстройства. Диагностика, систематика, семиотика, терапия. Томск; 2001. 130 с.

Kornetov NA. Depressivnye rasstroystva. Diagnostika, sistematika, semiotika, terapiya [Depressive disorders. Diagnostics, systematics, semiotics, therapy]. Tomsk; 2001. 130 p. (In Russ.).

Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991 May;52 Suppl:2834.

Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:5-9.

McIntyre R, Kennedy S, Bagby RM, Bakish D. Assessing full remission. J Psychiatry Neurosci. 2002 Jul;27(4):235-9.

Schueller SM, Kwasny MJ, Dear BF, et al. Cut points on the Patient Health Questionnaire (PHQ-9) that predict response to cognitivebehavioral treatments for depression. Gen Hosp Psychiatry. 2015 Sep-Oct;37(5):470-5. doi: 10.1016/j.genhosppsych.2015.05.009. Epub 2015 May 29.

Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011 Jun;41(6):1165-74. doi: 10.1017/S0033291710001911. Epub 2010 Oct 8.

Chehil S, Devarajan S, Dursun SM. Pharmacologic management of refractory depression. Can Fam Physician. 2001 Jan;47:50-2.

Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995 Nov;25(6):1171-80. doi: 10.1017/s0033291700033146

Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J Affect Disord. 2013 Oct;151(1):59-65. doi: 10.1016/j.jad.2013.05.048. Epub 2013 Jun 19.

Zimmerman M, Martinez JA, Attiullah N, et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry. 2012 Jun;73(6):790-5. doi: 10.4088/JCP.11m07203. Epub 2012 Apr 17.

Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993 Nov;54(11):405-18.

Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl. 1998;(34):4-9. doi: 10.1192/S0007125000293458

Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry. 2003 Dec;183:514-9. doi: 10.1192/bjp.183.6.514

Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003 Dec;64(12):1465-75. doi: 10.4088/jcp.v64n1211

Sobocki P, Lekander I, Borgström F, et al. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry. 2007 Apr;22(3):146-52. doi: 10.1016/j.eurpsy.2006.10.006. Epub 2006 Dec 27.

Volz HP, Bartecku E, Bartova L, et al. Sick leave duration as a potential marker of functionality and disease severity in depression. Int J Psychiatry Clin Pract. 2022 Nov;26(4):406-16. doi: 10.1080/13651501.2022.2054350. Epub 2022 Apr 2.

Habert J, Katzman MA, Oluboka OJ, et al. Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment. Prim Care Companion CNS Disord. 2016 Sep 1;18(5). doi: 10.4088/PCC.15r01926

McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009 Apr;29(3):243-59. doi: 10.1016/j.cpr.2009.01.005. Epub 2009 Feb 7.

Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010 Apr;24(4):267-84. doi: 10.2165/11530230-000000000-00000

Петрова НН. Новые цели терапии депрессии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(11):57-61. doi: 10.17116/jnevro202212211157

Petrova NN. New goals of depression therapy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(11):57-61. doi: 10.17116/jnevro202212211157 (In Russ.).

Yang H, Gao S, Li J, et al. Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression. Front Psychiatry. 2022 Jul 26;13:915689. doi: 10.3389/fpsyt.2022.915689

Oluboka OJ, Katzman MA, Habert J, et al. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol. 2018 Feb 1;21(2):12844. doi: 10.1093/ijnp/pyx081

МКБ-11. Глава 06. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. Под общей ред. Г.П. Костюка. Москва: КДУ, Университетская книга; 2021. 432 с. doi: 10.31453/kdu.ru.91304.0143. ISBN 978-5-91304-954-4

MKB-11. Glava 06. Psikhicheskie i povedencheskie rasstroystva i narusheniya neyropsikhicheskogo razvitiya. Statisticheskaya klassifikatsiya [ICD-11. Chapter 06. Mental and behavioral disorders and disorders of neuropsychic development. Statistical classification]. Under the general editorship of G.P. Kostyuk. Moscow: KDU, University book; 2021. 432 p. doi: 10.31453/kdu.ru.91304.0143. ISBN 978-591304-954-4 (In Russ.).

Нуллер ЮЛ. Структура психических расстройств. Киев: Сфера; 2008. С. 10-1.

Nuller YuL. Struktura psikhicheskikh rasstroystv [The structure of mental disorders]. Kiev: Sphere; 2008. P. 10-1 (In Russ.).

Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. Cambridge – New York: Cambridge University Press; 2013.

Волель БА. Вальдоксан (агомелатин): инновационный механизм действия. Психиатрия и психофармакотерапия. 2008;10(3):35-9.

Volel BA. Valdoxan (agomelatin): innovative mechanism of action. Psikhiatriya i psikhofarmakoterapiya = Psychiatry and psychopharmacotherapy. 2008;10(3):35-9 (In Russ.).

Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2

Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta analysis of published and unpublished studies. BMJ. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888. Erratum in: BMJ. 2014;348:g2496.

Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012 Apr;15(3):417-28. doi: 10.1017/S1461145711001301. Epub 2011 Aug 23.

Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-66. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21.

Иванов СВ. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского мультицентрового исследования «ХРОНОС»). Психиатрия и психофармакотерапия. 2009;11(6):14-7.

Ivanov SV. Valdoxan (agomelatin) in the treatment of moderate and severe depression of non-psychotic level in outpatient and hospital practice (results of the Russian multicenter study “CHRONOS”). Psikhiatriya i psikhofarmakoterapiya = Psychiatry and psychopharmacotherapy. 2009;11(6):14-7 (In Russ.).

Смулевич АБ, Андрющенко АВ, Бескова ДА. Терапия непсихотических депрессий антидепрессантом агомелатином (Вальдоксан): результаты наблюдательного многоцентрового исследования «РИТМ». Психиатрия и психофармакотерапия. 2010;12(4):4-11.

Smulevich AB, Andryushchenko AC, Beskova YeS. Therapy of non-psychotic depression with the antidepressant agomelatin (Valdoxan): the results of the observational multicenter study “RHYTHM”. Psikhiatriya i psikhofarmakoterapiya = Psychiatry and psychopharmacotherapy. 2010;12(4):4-11 (In Russ.).

Усов ГМ, Коломыцев ДЮ, Ломиашвили ЛМ. Влияние антидепрессантов разных классов на регуляцию процессов сна и бодрствования при депрессии. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):82-8. doi: 10.14412/2074-27112022-1-82-88

Usov GM, Kolomytsev DU, Lomiashvili LM. The effect of antidepressants of different classes on the regulation of sleep and wakefulness processes in depression. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):828. doi: 10.14412/2074-2711-2022-1-82-88 (In Russ.).

Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6. doi: 10.1017/S1461145707007754. Epub 2007 May 4.

Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi: 10.1097/YIC.0b013e328349b117

Полуэктов МГ, Левин ЯИ. Результаты российского мультицентрового открытого обсервационного несравнительного исследования эффективности и безопасности вальдоксана (агомелатин) при лечении пациентов с большим депрессивным расстройством и нарушениями сна (исследование ВИВАЛЬДИ). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(12):39-44.

Poluektov MG, Levin YaI. The results of the Russian multicenter open observational incomparable study of the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and sleep disorders (VIVALDI study). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(12):39-44 (In Russ.).

Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011 JanMar;25(1):109-14.

Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012 Aug;32(4):487-91. doi: 10.1097/JCP.0b013e31825d6c25

Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol. 2012;22 Suppl 3:S505-10. doi: 10.1016/j.euroneuro.2012.07.004

Медведев ВЭ, Гушанская ЕВ, Исраелян АЮ. Терапия депрессий с явлениями ангедонии (опыт применения вальдоксана). Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2014;16(3):45-9.

Medvedev VE, Gushanskaya EV, Israelyan AYu. Therapy of depression with symptoms of anhedonia (experience of valdoxan). Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2014;16(3):45-9. (In Russ.).

Llorca P, Gourion D. Management of Anhedonia and Depressive Symptoms in Depressed Outpatients: Benefit for Functioning. Eur Psychiatry. 2015;30(S1):364. doi: 10.1016/S0924-9338(15)31881-2

Demyttenaere K, Corruble E, Hale A, et al. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013 Jun;18(3):163-70. doi: 10.1017/S1092852913000060. Epub 2013 Mar 11.

Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Aug;70(8):1128-37. doi: 10.4088/JCP.08m04548. Epub 2009 Aug 11.

Khoo AL, Zhou HJ, Teng M, et al. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs. 2015 Aug;29(8):695-712. doi: 10.1007/s40263-015-0267-6

Kennedy SH, Avedisova A, Belaidi C, et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016 Feb;26(2):378-89. doi: 10.1016/j.euroneuro.2015.09.006. Epub 2015 Sep 25.

Kennedy SH, Heun R, Avedisova A, et al. Effect of agomelatine 25–50 mg on functional outcomes in patients with major depressive disorder. J Affect Disord. 2018 Oct 1;238:122-8. doi: 10.1016/j.jad.2018.05.060. Epub 2018 May 29.

Geschwind N, Nicolson NA, Peeters F, et al. Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. Eur Neuropsychopharmacol. 2011 Mar;21(3):241-7. doi: 10.1016/j.euroneuro.2010.11.004. Epub 2010 Dec 13.

Hallford DJ, Rusanov D, Yeow JJE, et al. Reducing Anhedonia in Major Depressive Disorder with Future Event Specificity Training (FEST): A Randomized Controlled Trial. Cogn Ther Res. 2023;47:20-37. doi: 10.1007/s10608022-10330-z

Медведев ВЭ, Ретюнский КЮ, Овчинников АА и др. Различия в оценке тяжести депрессии врачами и пациентами в процессе комбинированной терапии агомелатином (мультицентровое исследование «ЭМОЦИЯ»). Журнал неврологии и психиатрии им. С.С. Корсакова. 2016;116(11):26-34. doi: 10.17116/jnevro201611611126-34

Medvedev VE, Retyunsky KYu, Ovchinnikov A, et al. Differences in the assessment of the severity of depression by doctors and patients during combination therapy with agomelatin (multicenter study “EMOTION”). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(11):26-34. doi: 10.17116/jnevro201611611126-34 (In Russ.).

Medvedev V, Retyunskii K, Ovchinnikov A, et al. Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial). Neurosci Behav Physiol. 2018;48(3):367-76. doi: 10.1007/s11055-018-0572-x

Cao B, Xu L, Chen Y, et al. Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis. CNS Spectr. 2021 Feb 15;1-9. doi: 10.1017/S1092852921000171. Online ahead of print.

The authors declare that there are no conflicts of interest present.